Target-controlled infusion vs. standard dosing of cefoxitin for surgical prophylaxis in colorectal surgery: a randomized clinical trial
Clinical Microbiology and Infection · 2026-09 · 32 (9) · 1503-1509
DOI: 10.1016/j.cmi.2026.03.019 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Microbiology and Infection, 2026-09. Verfasst von Jong Lyul Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Colon and Rectal Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Antibiotic Prophylaxis, Cefoxitin, Colorectal Surgery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES To compare the incidence of surgical site infection (SSI) between patients receiving cefoxitin via target-controlled infusion (TCI) and those receiving standard dosing during colorectal surgery, and to evaluate differences in intraoperative antibiotic exposure and postoperative safety outcomes. METHODS In this single-center, parallel-arm randomized clinical trial, 2,494 adults undergoing elective colorectal surgery between April 2022 and July 2025 were assigned to receive cefoxitin via TCI or the standard dosing method. The TCI group received cefoxitin through a pharmacokinetic model-driven infusion pump targeting a plasma concentration of 80 μg/mL until the end of surgery, whereas the standard group received 2 g every 2 hours up to 8 g. The primary endpoint was the incidence of surgical site infection (SSI) within 30 days postoperatively. Secondary endpoints included intraoperative cumulative cefoxitin dose. Acute kidney injury (AKI) was assessed as an additional safety endpoint. RESULTS No statistically significant difference in SSI incidence was detected between groups (TCI: 69/1,224 (5.6%) vs standard: 69/1,233 (5.6%); P=0.965; RR: 1.01; 95% CI: 0.73-1.39). The intraoperative cumulative cefoxitin dose was lower in the TCI group (median 1.38 g [IQR, 1.15-1.71]) than in the standard group (2.00 g [2.00-4.00]); Mann-Whitney P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Colon and Rectal Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Statistics, Ewha Womans University, Seoul, Republic of Korea.
- Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: byungmoonchoi7@gmail.com.
Zitieren
APA
Lee, J. L., Kim, H. J., Kim, K. M., Yi, J. M., Oh, J., Lee, E. K., Choi, B. M., & Park, I. J. (2026). Target-controlled infusion vs. standard dosing of cefoxitin for surgical prophylaxis in colorectal surgery: a randomized clinical trial. Clinical Microbiology and Infection, 32(9), 1503-1509. https://doi.org/10.1016/j.cmi.2026.03.019
Vancouver
Lee JL, Kim HJ, Kim KM, Yi JM, Oh J, Lee EK, et al. Target-controlled infusion vs. standard dosing of cefoxitin for surgical prophylaxis in colorectal surgery: a randomized clinical trial. Clinical Microbiology and Infection. 2026;32(9):1503-1509. doi:10.1016/j.cmi.2026.03.019
BibTeX
@article{Lee2026,
author = {Lee, Jong Lyul and Kim, Ha-Jung and Kim, Kyung Mi and Yi, Jung-Min and Oh, Juyeon and Lee, Eun-Kyung and Choi, Byung-Moon and Park, In Ja},
title = {Target-controlled infusion vs. standard dosing of cefoxitin for surgical prophylaxis in colorectal surgery: a randomized clinical trial},
journal = {Clinical Microbiology and Infection},
year = {2026},
volume = {32},
number = {9},
pages = {1503--1509},
doi = {10.1016/j.cmi.2026.03.019}
}
EUVIMED